|
[1]
|
Ferlay, J., et al. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Venook, A.P., et al. (2010) The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. Oncologist, 154, 5-13. [Google Scholar] [CrossRef]
|
|
[3]
|
Altekruse, S.F., McGlynn, K.A. and Reichman, M.E. (2009) Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States from 1975 to 2005. Journal of Clinical Oncology, 27, 1485-1491. [Google Scholar] [CrossRef]
|
|
[4]
|
Llovet, J.M., et al. (1999) Natural History of Untreated Nonsur-gical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials. Hepatology (Baltimore, MD), 29, 62-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Hu, H., et al. (2017) Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus. Biological Trace Element Research, 1-7. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Takami, K., et al. (2002) Interferon-Gamma Inhibits Hepatocyte Growth Factor-Stimulated Cell Proliferation of Human Bronchial Epithelial Cells: Upregulation of p27kip1 Cyc-lin-Dependent Kinase Inhibitor. American Journal of Respiratory Cell and Molecular Biology, 26, 231-238. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Yu, R., et al. (2014) DR4 Specific TRAIL Variants Are More Ef-ficacious than Wild-Type TRAIL in Pancreatic Cancer. Cancer Biology & Therapy, 15, 1658-1666. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Willimsky, G., et al. (2008) Immunogenicity of Premalignant Lesions Is the Primary Cause of General Cytotoxic T Lymphocyte Unresponsiveness. Journal of Experimental Medicine, 205, 1687-1700. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Lee, I., et al. (2013) Serum Interferon Gamma Level Predicts Recur-rence in Hepatocellular Carcinoma Patients after Curative Treatments. International Journal of Cancer, 133, 2895-2902. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
程广霞, 等. 原发性肝癌血清细胞因子检测的临床意义[J]. 中国现代普通外科进展, 2016, 19(12): 990-991+995.
|
|
[11]
|
Tibaldi, L., et al. (2013) New Blocking Antibodies Impede Adhesion, Migration and Survival of Ovarian Cancer Cells, Highlighting MFGE8 as a Potential Therapeutic Target of Human Ovarian Carcinoma. PLoS ONE, 8, e727088. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Grace, S.A., et al. (2017) Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adeno-carcinoma. Anticancer Research, 37, 699-703. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Bie, B., et al. (2017) Baicalein: A Review of Its Anti-Cancer Effects and Mechanisms in Hepatocellular Carcinoma. Biomedicine & Pharmacotherapy, 93, 1285-1291. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Bletry, O. and Papo, T. (1993) Interferons. Interferons Alpha and Gamma: Indications in Systemic Diseases. Annales de Medecine Interne, 144, 557-562.
|
|
[15]
|
Stark, G.R. (2007) How Cells Respond to Interferons Revisited: From Early History to Current Complexity. Cytokine & Growth Factor Reviews, 18, 419-423. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
李世朋, 等. 干扰素γ抑制自噬诱导肝癌HepG2细胞凋亡的作用[J]. 中国临床药理学杂志, 2017, 33(4): 343-346.
|
|
[17]
|
Sunny, N.E., et al. (2011) Exces-sive Hepatic Mitochondrial TCA Cycle and Gluconeogenesis in Humans with Nonalcoholic Fatty Liver Disease. Cell Metabolism, 14, 804-810. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Savan, R. (2014) Post-Transcriptional Regulation of Interferons and Their Signaling Pathways. Journal of Interferon and Cytokine Research, 34, 318-329. [Google Scholar] [CrossRef] [PubMed]
|